Takeda’s chief executive admitted that his company used “inappropriate expressions” in promotions of its blood pressure drug Blopress, reports the Wall Street Journal. The Journal notes that the CEO’s statement comes after Japan’s health ministry said it was going to examine the company’s advertisements which used a graph that did not align with clinical trial results that compared Blopress and Pfizer’s Norvasc.
The Journal says the company also “admitted using expressions in its ads that could potentially lead to misunderstanding that Takeda’s drug was more effective than the rival product.”
